C1 Esterase Inhibitor (Intravenous) therapies for Hereditary Angioedema (Berinert, Cinryze, Ruconest)
Defines medical necessity, prior authorization expectations, dosing limits, and coverage exclusions for IV C1-esterase inhibitor products (Berinert, Cinryze, Ruconest) for treatment and prophylaxis of hereditary angioedema (HAE). Applies to requests for medical-benefit coverage and to prescribers/providers managing HAE therapy.
Patients who previously met initial therapy criteria through the Coverage Review Department and are currently receiving therapy only need to meet continuation criteria; if prior approval was obtained elsewhere the patient must meet initial criteria.
Deleted the bracketed phrase '[Type I or Type II]' from multiple indication headings (prophylaxis and acute treatment sections).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.